Enhancing siRNA efficacy in vivo with extended nucleic acid backbones-Reference-Cited by-同舟云学术

Enhancing siRNA efficacy in vivo with extended nucleic acid backbones

Published:2024-08-01 Issue: Volume: Page:
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Yamada Ken^ORCID,Hariharan Vignesh N.^ORCID,Caiazzi Jillian^ORCID,Miller Rachael^ORCID,Ferguson Chantal M.^ORCID,Sapp Ellen,Fakih Hassan H.^ORCID,Tang Qi^ORCID,Yamada Nozomi,Furgal Raymond C.^ORCID,Paquette Joseph D.^ORCID,Biscans Annabelle,Bramato Brianna M.,McHugh Nicholas^ORCID,Summers Ashley^ORCID,Lochmann Clemens^ORCID,Godinho Bruno M. D. C.^ORCID,Hildebrand Samuel,Jackson Samuel O.^ORCID,Echeverria Dimas,Hassler Matthew R.^ORCID,Alterman Julia F.^ORCID,DiFiglia Marian,Aronin Neil,Khvorova Anastasia^ORCID

Funder

CHDI Foundation

U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke

MIRA: NIH grant for Maximizing Investigator's Research Award S10: NIH grant of Instrumentation Program

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41587-024-02336-7.pdf

Reference90 articles.

1. Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017).

2. Crooke, S. T. et al. RNA targeted therapeutics. Cell Metab. 27, 714–739 (2018).

3. Levin, A. A. Treating disease at the RNA level with oligonucleotides. N. Engl. J. Med. 380, 57–70 (2019).

4. Shen, X. & Corey, D. R. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 46, 1584–1600 (2018).

5. Egli, M. & Manoharan, M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 51, 2529–2573 (2023).